This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
by Zacks Equity Research
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Bausch Acquires License for Myopia Solution from Eyenovia
by Zacks Equity Research
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
Eton Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eton Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 17.86% and -93.85%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -108.33% and -93.89%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals Inc (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Eton Pharmaceuticals Inc (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eton Pharmaceuticals, Inc. (ETON) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Eton Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Eton Pharmaceuticals
Company News for Mar 30, 2020
by Zacks Equity Research
Companies in the news are: ETON, SDC, RRTS, BKYI
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 48.28% and -54.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q4 performance is likely to have benefited from increased membership and visits.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
by Zacks Equity Research
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
by Zacks Equity Research
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.